Date: 2015-09-01
Type of information: Nomination
Compound:
Company: Ose Pharma (France)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 1st, 2015, OSE Pharma, a biotechnology company based in France that is developing T-specific immunotherapy treatments against invasive and metastatic cancers, is pleased to announce the formation of its International Scientific Steering Committee as a part of the launch of its pivotal Phase 3 trial of Tedopi® by the end of the year. The creation of this Scientific Steering Committee is a key step for OSE Pharma in finalizing its .
phase III trial’s protocol. The Committee will be in charge of making decisions regarding the monitoring of the clinical study, in consultation with an independent monitoring committee. The International Scientific Steering Committee consists of 4 members:
- Dr. Benjamin Besse, Oncologist and Head of the Thoracic Pathology Committee at the Institut Gustave Roussy in Paris, will chair the Scientific Steering Committee,
- Pr. Giuseppe Giaconne, Associate Director of Clinical Research at the Georgetown Lombardi Comprehensive Cancer Center, will co-chair the Committee in the United States, with
- Dr. Enriqueta Felip, Head of the Thoracic Tumors Group at Vall d\'Hebron Institute of Oncology in Barcelona, and
- Dr. Rafal Dziadziuszko, Assistant Professor in the Department of Oncology and Radiotherapy of the Medical University of Gdansk.
Financial terms:
Latest news:
